A Phase 3 interventional study of R89674 (generic name not yet established) in Healthy Volunteers Eligible for Study; Drug Being Developed for Allergic Conjunctivitis, sponsored by Vistakon Pharmaceuticals. Completed at 6 sites in United States. Open to participants aged 3 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2015-02-20.
Sponsored by Vistakon Pharmaceuticals · Phase 3, Interventional, and Treatment
The purpose of this study is to evaluate the safety of R89674 0.25% ophthalmic solution in healthy normal volunteers
231 studies on the registry are indexed under Conjunctivitis, Allergic; 19 are open to participants now.
This study's enrollment of 900 is above the median of 85 across 192 interventional studies indexed under Conjunctivitis, Allergic.
Browse Conjunctivitis, Allergic studies →Vistakon Pharmaceuticals is the lead sponsor of 13 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
healthy normal volunteers age >=3 years with normal ocular health and a best-corrected logMAR score of 0.3 or better
-
Exclusion Criteria:
intraocular surgery and/or ocular surgical intervention within last 3 months, refractive surgery within last 6 months, active ocular disorder other than refractive disorders, breastfeeding women, pregnant female \< 18 years of age -
Adverse events; biomicroscopy and visual acuity at baseline and Days 7, 21, and 42; ophthalmoscopy and intraocular pressure at baseline and Day 42; physical examination
No additional endpoints
The record gives a start of Sep 2005 and a primary completion of Dec 2005. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Alcaftadine
Vistakon Pharmaceuticals